These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 28417311)

  • 21. Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors.
    Jindal V; Gupta S
    Mol Neurobiol; 2018 Aug; 55(8):7072-7078. PubMed ID: 29383686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies.
    Du Four S; Wilgenhof S; Duerinck J; Michotte A; Van Binst A; De Ridder M; Neyns B
    Eur J Cancer; 2012 Nov; 48(16):3045-51. PubMed ID: 22727601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives.
    Atkins MB; Larkin J
    J Natl Cancer Inst; 2016 Jun; 108(6):djv414. PubMed ID: 26839346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
    Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
    Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.
    Nunno VD; Nuvola G; Mosca M; Maggio I; Gatto L; Tosoni A; Lodi R; Franceschi E; Brandes AA
    Immunotherapy; 2021 Apr; 13(5):419-432. PubMed ID: 33472433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.
    Geukes Foppen MH; Brandsma D; Blank CU; van Thienen JV; Haanen JB; Boogerd W
    Ann Oncol; 2016 Jun; 27(6):1138-1142. PubMed ID: 26961150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab.
    Frenard C; Peuvrel L; Jean MS; Brocard A; Knol AC; Nguyen JM; Khammari A; Quereux G; Dreno B
    J Neurooncol; 2016 Jan; 126(2):355-60. PubMed ID: 26511495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy.
    Kaidar-Person O; Zagar TM; Deal A; Moschos SJ; Ewend MG; Sasaki-Adams D; Lee CB; Collichio FA; Fried D; Marks LB; Chera BS
    Anticancer Drugs; 2017 Jul; 28(6):669-675. PubMed ID: 28368903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy targeting immune check-point(s) in brain metastases.
    Di Giacomo AM; Valente M; Covre A; Danielli R; Maio M
    Cytokine Growth Factor Rev; 2017 Aug; 36():33-38. PubMed ID: 28736183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions.
    Atkins M
    Semin Oncol; 2015 Dec; 42 Suppl 3():S12-9. PubMed ID: 26598055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis.
    Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Lee EQ; Aizer AA; Guenette JP; Huang RY
    Korean J Radiol; 2021 Apr; 22(4):584-595. PubMed ID: 33289357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin.
    Kattan J; Rassy EE; Assi T; Bakouny Z; Pavlidis N
    Crit Rev Oncol Hematol; 2018 Oct; 130():60-69. PubMed ID: 30196913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons.
    Aquilanti E; Brastianos PK
    Neurosurgery; 2020 Sep; 87(3):E281-E288. PubMed ID: 32302389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
    Margolin KA; Di Giacomo AM; Maio M
    Semin Oncol; 2010 Oct; 37(5):468-72. PubMed ID: 21074062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel therapeutic agents in the management of brain metastases.
    Venur VA; Ahluwalia MS
    Curr Opin Oncol; 2017 Sep; 29(5):395-399. PubMed ID: 28787285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response.
    Yusuf MB; Amsbaugh MJ; Burton E; Chesney J; Woo S
    World Neurosurg; 2017 Apr; 100():632-640.e4. PubMed ID: 28179176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical Approaches to Immunotherapy in the Clinic.
    Agarwala SS
    Semin Oncol; 2015 Dec; 42 Suppl 3():S20-7. PubMed ID: 26598056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases.
    Moraes FY; Taunk NK; Marta GN; Suh JH; Yamada Y
    Oncologist; 2016 Feb; 21(2):244-51. PubMed ID: 26764249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series.
    Jones PS; Cahill DP; Brastianos PK; Flaherty KT; Curry WT
    Neurosurg Focus; 2015 Mar; 38(3):E5. PubMed ID: 25727227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.